Evidence map›Paper›PMID 33814466›Full record

ReviewJournal of Parkinson's disease2021

Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson's Disease to the Clinic: The Investigator's Perspective.

Roger A Barker, Emma V Cutting, Danielle M Daft

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Roger A BarkerDepartment of Clinical Neuroscience, University of Cambridge, Forvie Site, Robinson Way, Cambridge, UK.
Emma V CuttingDepartment of Clinical Neuroscience, University of Cambridge, Forvie Site, Robinson Way, Cambridge, UK.
Danielle M DaftDepartment of Clinical Neuroscience, University of Cambridge, Forvie Site, Robinson Way, Cambridge, UK.
University of Cambridge · GBWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Medical Research Council MC_PC_17230Medical Research Council MR/R015724/1Wellcome Trust
6 · The paper itself

Abstract

There is much excitement around the use of advanced therapy medicinal products (ATMPs), including cell and gene treatments, in Parkinson's disease (PD). However, taking an ATMP to clinical trials in patients with PD is complex. As such it is important from an investigator's perspective that they ask themselves two key questions before embarking on such work: firstly, why are you doing it, and, secondly, do you understand what is needed to conduct a clinical trial with that product. In this article, we briefly discuss these two questions.

Indexed as

Parkinson DiseaseHumansATMPclinical trialgene therapyParkinson’s diseaseregulationsstem cells

Identifiers

PMID33814466
PMCPMC8543259
OpenAlexW3141827265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.